Alpha-1 Deficiency Medical Resources

Medical Resources

Medical Affairs Center

Phone: 1-800-504-5434
Fax: 610-878-4007
E-mail: medinfona@CSLbehring.com

Medical Information
North America Headquarters
CSL Behring
P.O. Box 61501
1020 First Avenue
King of Prussia, PA 19406 USA

Scientific Support

Continuing Education. The Alpha-1 Foundation offers a CME program to help educate healthcare professionals on the standards for the diagnosis and management of Alpha-1 deficiency. For more information about this CME, please visit the Alpha-1 Foundation home page and select the Programs option. On the Programs page, select the CME option on the left side of the page.

Web Resources.

The Alpha-1 Foundation is dedicated to providing leadership and resources to increase research, improve health, and result in the worldwide detection of and a cure for Alpha-1 deficiency. This site contains an excellent explanation of Alpha-1 deficiency, provides health tips, and offers a free Alpha-1 testing kit.

The American Thoracic Society focuses on respiratory and critical care medicine, with a long-range goal of decreasing morbidity and mortality from respiratory disorders and life-threatening acute illnesses. The Society helps to set the standards for prevention, treatment, and control of these serious diseases.

Accredo Therapeutics, the distributor for Zemaira^®, is the country's most extensive network of pharmacies dedicated to the treatment of Alpha-1 deficiency, as well as pulmonary arterial hypertension (PAH) and disorders requiring intravenous immunoglobulin (IVIg) therapy.

Coram is a leader in home infusion services and specialty pharmacy distribution, proudly distributing Zemaira^® through more than 75 locations nationwide. Having years of experience, Coram is committed to the care of those living with Alpha-1 as well as the Alpha-1 community.

Journal Reprints. Select any of the following journal articles on Alpha-1 deficiency or Zemaira® that may be of interest to you. CSL Behring will send your selection(s), as well as future updates on AAT Deficiency and Zemaira®, via e-mail.^*

Stocks JM, Brantly M, Pollock D, et al. Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha₁-proteinase inhibitor, Zemaira. COPD. 2006;3:17-23.

Kueppers F, Patel U. Differences in microheterogeneity and non-therapeutic protein content of three commercial preparations of purified human alpha1-proteinase inhibitor (abstract).

Stocks JM, Spencer LT, Pollock DP, Brantly ML. Lower respiratory tract biochemical efficacy of intravenous administration of a new form of highly purified alpha₁-antitrypsin (abstract).

Stocks JM, Brantly M, Barker A, et al. Comparable pharmacokinetic properties of two alpha¹-proteinase inhibitors after single therapeutic doses (abstract).

Please complete the fields below to receive your selected readings

* Indicates required field.

Title
*First Name
*Last Name
*Address 1
Address 2
*City
*State
*ZIP or Postal Code
*E-mail
Specialty
- *Type in the verification word in the box below (case sensitive):

^* This list of resources is provided as a service by CSL Behring LLC. Publication of these resources by CSL Behring does not necessarily constitute our approval or endorsement of viewpoints, inferences, or conclusions stated in or implied by the authors of these materials. Listed resources were accurate at the time of publication. CSL Behring LLC is not responsible for changes in resource information.

Important Safety Information

Alpha₁-Proteinase Inhibitor (Human), Zemaira is indicated for chronic augmentation and maintenance therapy for adults with alpha₁-proteinase inhibitor (A₁-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A₁-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.